Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: An evaluation framework
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
Fersiynau electronig
Dogfennau
- Methods for assessing the cost effectiveness of a PGx panel CPT ACCEPTED
Llawysgrif awdur wedi’i dderbyn, 0.98 MB, dogfen-PDF
Dangosydd eitem ddigidol (DOI)
The cost-effectiveness of testing for multiple genes implicated in adverse drug reactions requires the simultaneous assessment of all actionable information, including future prescribing decisions based on incidental findings. We developed methodology for determining the value of pharmacogenetic panel tests, illustrated with a multi-gene panel including HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, HLA-B*58:01, HLA-B (158T) and HLA-DQB1 (126Q). If the findings for all alleles are acted upon, regardless of their individual cost-effectiveness, the HLA panel resulted in cost savings of £378 (US$491), and a QALY gain of 0.0069. Based on a stratified analysis and compared with no testing, initial use of the panel was cost-effective in patients eligible for abacavir (HLA-B*57:01), carbamazepine (HLA-A*31:01) and clozapine (HLA-B (158T) and HLA-DQB1 (126Q)) but not for carbamazepine (HLA-B*15:02) or allopurinol (HLA-B*58:01). The methods presented allow for the assessment of the cost-effectiveness of multiple-gene panels.
Iaith wreiddiol | Saesneg |
---|---|
Tudalennau (o-i) | 1429-1438 |
Cyfnodolyn | Clinical Pharmacology and Therapeutics |
Cyfrol | 105 |
Rhif y cyfnodolyn | 6 |
Dyddiad ar-lein cynnar | 22 Tach 2018 |
Dynodwyr Gwrthrych Digidol (DOIs) | |
Statws | Cyhoeddwyd - Meh 2019 |
Cyfanswm lawlrlwytho
Nid oes data ar gael